Английская Википедия:Herpes simplex virus

Материал из Онлайн справочника
Перейти к навигацииПерейти к поиску

Шаблон:Short description Шаблон:Cs1 config Шаблон:About Шаблон:Paraphyletic group

Herpes simplex virus 1 and 2 (HSV-1 and HSV-2), also known by their taxonomic names Human alphaherpesvirus 1 and Human alphaherpesvirus 2, are two members of the human Herpesviridae family, a set of viruses that produce viral infections in the majority of humans.[1][2] Both HSV-1 and HSV-2 are very common and contagious. They can be spread when an infected person begins shedding the virus.

As of 2016, about 67% of the world population under the age of 50 had HSV-1.[3] In the United States, about 47.8% and 11.9% are estimated to have HSV-1 and HSV-2, respectively, though actual prevalence may be much higher.[4] Because it can be transmitted through any intimate contact, it is one of the most common sexually transmitted infections.[5]

Symptoms

Many of those who are infected never develop symptoms.[6] Symptoms, when they occur, may include watery blisters in the skin or mucous membranes of the mouth, lips, nose, genitals,[1] or eyes (herpes simplex keratitis).[7] Lesions heal with a scab characteristic of herpetic disease. Sometimes, the viruses cause mild or atypical symptoms during outbreaks. However, they can also cause more troublesome forms of herpes simplex. As neurotropic and neuroinvasive viruses, HSV-1 and -2 persist in the body by hiding from the immune system in the cell bodies of neurons, particularly in sensory ganglia. After the initial or primary infection, some infected people experience sporadic episodes of viral reactivation or outbreaks. In an outbreak, the virus in a nerve cell becomes active and is transported via the neuron's axon to the skin, where virus replication and shedding occur and may cause new sores.[8]

Transmission

Шаблон:Main HSV-1 and HSV-2 are transmitted by contact with an infected person who has reactivations of the virus. HSV 1 and HSV-2 are periodically shed, most often asymptomatically. Шаблон:Citation needed

In a study of people with first-episode genital HSV-1 infection from 2022, genital shedding of HSV-1 was detected on 12% of days at 2 months and declined significantly to 7% of days at 11 months. Most genital shedding was asymptomatic; genital and oral lesions and oral shedding were rare.[9]

Most sexual transmissions of HSV-2 occur during periods of asymptomatic shedding.[10] Asymptomatic reactivation means that the virus causes atypical, subtle, or hard-to-notice symptoms that are not identified as an active herpes infection, so acquiring the virus is possible even if no active HSV blisters or sores are present. In one study, daily genital swab samples detected HSV-2 at a median of 12–28% of days among those who had an outbreak, and 10% of days among those with asymptomatic infection (no prior outbreaks), with many of these episodes occurring without visible outbreak ("subclinical shedding").[11]

In another study, 73 subjects were randomized to receive valaciclovir 1 g daily or placebo for 60 days each in a two-way crossover design. A daily swab of the genital area was self-collected for HSV-2 detection by polymerase chain reaction, to compare the effect of valaciclovir versus placebo on asymptomatic viral shedding in immunocompetent, HSV-2 seropositive subjects without a history of symptomatic genital herpes infection. The study found that valaciclovir significantly reduced shedding during subclinical days compared to placebo, showing a 71% reduction; 84% of subjects had no shedding while receiving valaciclovir versus 54% of subjects on placebo. About 88% of patients treated with valaciclovir had no recognized signs or symptoms versus 77% for placebo.[12]

For HSV-2, subclinical shedding may account for most of the transmission.[11] Studies on discordant partners (one infected with HSV-2, one not) show that the transmission rate is approximately 5–8.9 per 10,000 sexual contacts, with condom usage greatly reducing the risk of acquisition.[13] Atypical symptoms are often attributed to other causes, such as a yeast infection.[14][15] HSV-1 is often acquired orally during childhood. It may also be sexually transmitted, including contact with saliva, such as kissing and oral sex.[16] Historically HSV-2 was primarily a sexually transmitted infection, but rates of HSV-1 genital infections have been increasing for the last few decades.[14]

Both viruses may also be transmitted vertically during childbirth.[17][18] However, the risk of transmission is minimal if the mother has no symptoms nor exposed blisters during delivery. The risk is considerable when the mother is infected with the virus for the first time during late pregnancy, reflecting high viral load.[19] While most viral STDs can not be transmitted through objects as the virus dies quickly outside of the body, HSV can survive for up to 4.5 hours on surfaces and can be transmitted through use of towels, toothbrushes, cups, cutlery, etc.[20][21][22][23]

Herpes simplex viruses can affect areas of skin exposed to contact with an infected person. An example of this is herpetic whitlow, which is a herpes infection on the fingers; it was commonly found on dental surgeon's hands prior to the routine use of gloves when treating patients. Shaking hands with an infected person does not transmit this disease.[24] Genital infection of HSV-2 increases the risk of acquiring HIV.[25]

Virology

HSV has been a model virus for many studies in molecular biology. For instance, one of the first functional promoters in eukaryotes was discovered in HSV (of the thymidine kinase gene) and the virion protein VP16 is one of the most-studied transcriptional activators.[26]

Viral Structure

Файл:A-Tail-like-Assembly-at-the-Portal-Vertex-in-Intact-Herpes-Simplex-Type-1-Virions-ppat.1002961.s003.ogv
A three-dimensional reconstruction and animation of a tail-like assembly on HSV-1 capsid
Файл:HSV-1-EM.png
3D reconstruction of the HSV-1 capsid
Файл:HSV 2.jpg
Herpes simplex virus 2 capsid

Animal herpes viruses all share some common properties. The structure of herpes viruses consists of a relatively large, double-stranded, linear DNA genome encased within an icosahedral protein cage called the capsid, which is wrapped in a lipid bilayer called the envelope. The envelope is joined to the capsid by means of a tegument. This complete particle is known as the virion.[27] HSV-1 and HSV-2 each contain at least 74 genes (or open reading frames, ORFs) within their genomes,[28] although speculation over gene crowding allows as many as 84 unique protein coding genes by 94 putative ORFs.[29] These genes encode a variety of proteins involved in forming the capsid, tegument and envelope of the virus, as well as controlling the replication and infectivity of the virus. These genes and their functions are summarized in the table below.Шаблон:Citation needed

The genomes of HSV-1 and HSV-2 are complex and contain two unique regions called the long unique region (UL) and the short unique region (US). Of the 74 known ORFs, UL contains 56 viral genes, whereas US contains only 12.[28] Transcription of HSV genes is catalyzed by RNA polymerase II of the infected host.[28] Immediate early genes, which encode proteins for example ICP22[30] that regulate the expression of early and late viral genes, are the first to be expressed following infection. Early gene expression follows, to allow the synthesis of enzymes involved in DNA replication and the production of certain envelope glycoproteins. Expression of late genes occurs last; this group of genes predominantly encode proteins that form the virion particle.[28]

Five proteins from (UL) form the viral capsid - UL6, UL18, UL35, UL38, and the major capsid protein UL19.[27]

Cellular Entry

Файл:HSV replication.png
A simplified diagram of HSV replication

Entry of HSV into a host cell involves several glycoproteins on the surface of the enveloped virus binding to their transmembrane receptors on the cell surface. Many of these receptors are then pulled inwards by the cell, which is thought to open a ring of three gHgL heterodimers stabilizing a compact conformation of the gB glycoprotein, so that it springs out and punctures the cell membrane.[31] The envelope covering the virus particle then fuses with the cell membrane, creating a pore through which the contents of the viral envelope enters the host cell.Шаблон:Citation needed

The sequential stages of HSV entry are analogous to those of other viruses. At first, complementary receptors on the virus and the cell surface bring the viral and cell membranes into proximity. Interactions of these molecules then form a stable entry pore through which the viral envelope contents are introduced to the host cell. The virus can also be endocytosed after binding to the receptors, and the fusion could occur at the endosome. In electron micrographs, the outer leaflets of the viral and cellular lipid bilayers have been seen merged;[32] this hemifusion may be on the usual path to entry or it may usually be an arrested state more likely to be captured than a transient entry mechanism.Шаблон:Citation needed

In the case of a herpes virus, initial interactions occur when two viral envelope glycoprotein called glycoprotein C (gC) and glycoprotein B (gB) bind to a cell surface polysaccharide called heparan sulfate. Next, the major receptor binding protein, glycoprotein D (gD), binds specifically to at least one of three known entry receptors.[33] These cell receptors include herpesvirus entry mediator (HVEM), nectin-1 and 3-O sulfated heparan sulfate. The nectin receptors usually produce cell-cell adhesion, to provide a strong point of attachment for the virus to the host cell.[31] These interactions bring the membrane surfaces into mutual proximity and allow for other glycoproteins embedded in the viral envelope to interact with other cell surface molecules. Once bound to the HVEM, gD changes its conformation and interacts with viral glycoproteins H (gH) and L (gL), which form a complex. The interaction of these membrane proteins may result in a hemifusion state. gB interaction with the gH/gL complex creates an entry pore for the viral capsid.[32] gB interacts with glycosaminoglycans on the surface of the host cell. Шаблон:Citation needed

Genetic Inoculation

After the viral capsid enters the cellular cytoplasm, it starts to express viral protein ICP27. ICP27 is a regulator protein that causes disruption in host protein synthesis and utilizes it for viral replication. ICP27 binds with a cellular enzyme Serine-Arginine Protein Kinase 1, SRPK1. Formation of this complex causes the SRPK1 shift from the cytoplasm to the nucleus, and the viral genome gets transported to the cell nucleus.[34] Once attached to the nucleus at a nuclear entry pore, the capsid ejects its DNA contents via the capsid portal. The capsid portal is formed by 12 copies of portal protein, UL6, arranged as a ring; the proteins contain a leucine zipper sequence of amino acids, which allow them to adhere to each other.[35] Each icosahedral capsid contains a single portal, located in one vertex.[36][37] The DNA exits the capsid in a single linear segment.[38]

Immune Evasion

HSV evades the immune system through interference with MHC class I antigen presentation on the cell surface, by blocking the transporter associated with antigen processing (TAP) induced by the secretion of ICP-47 by HSV. In the host cell, TAP transports digested viral antigen epitope peptides from the cytosol to the endoplasmic reticulum, allowing these epitopes to be combined with MHC class I molecules and presented on the surface of the cell. Viral epitope presentation with MHC class I is a requirement for activation of cytotoxic T-lymphocytes (CTLs), the major effectors of the cell-mediated immune response against virally-infected cells. ICP-47 prevents initiation of a CTL-response against HSV, allowing the virus to survive for a protracted period in the host.[39] HSV usually produces cytopathic effect (CPE) within 24–72 hours post-infection in permissive cell lines which is observed by classical plaque formation. However, HSV-1 clinical isolates have also been reported that did not show any CPE in Vero and A549 cell cultures over several passages with low level of virus protein expression. Probably these HSV-1 isolates are evolving towards a more "cryptic" form to establish chronic infection thereby unravelling yet another strategy to evade the host immune system, besides neuronal latency.[40]

Replication

Файл:Herpes simplex virus pap test.jpg
Micrograph showing the viral cytopathic effect of HSV (multinucleation, ground glass chromatin)

Following infection of a cell, a cascade of herpes virus proteins, called immediate-early, early, and late, is produced. Research using flow cytometry on another member of the herpes virus family, Kaposi's sarcoma-associated herpesvirus, indicates the possibility of an additional lytic stage, delayed-late.[41] These stages of lytic infection, particularly late lytic, are distinct from the latency stage. In the case of HSV-1, no protein products are detected during latency, whereas they are detected during the lytic cycle.Шаблон:Citation needed

The early proteins transcribed are used in the regulation of genetic replication of the virus. On entering the cell, an α-TIF protein joins the viral particle and aids in immediate-early transcription. The virion host shutoff protein (VHS or UL41) is very important to viral replication.[42] This enzyme shuts off protein synthesis in the host, degrades host mRNA, helps in viral replication, and regulates gene expression of viral proteins. The viral genome immediately travels to the nucleus, but the VHS protein remains in the cytoplasm.[43][44]

The late proteins form the capsid and the receptors on the surface of the virus. Packaging of the viral particles — including the genome, core and the capsid - occurs in the nucleus of the cell. Here, concatemers of the viral genome are separated by cleavage and are placed into formed capsids. HSV-1 undergoes a process of primary and secondary envelopment. The primary envelope is acquired by budding into the inner nuclear membrane of the cell. This then fuses with the outer nuclear membrane. The virus acquires its final envelope by budding into cytoplasmic vesicles.[45]

Latent Infection

HSVs may persist in a quiescent but persistent form known as latent infection, notably in neural ganglia.[1] The HSV genome circular DNA resides in the cell nucleus as an episome.[46] HSV-1 tends to reside in the trigeminal ganglia, while HSV-2 tends to reside in the sacral ganglia, but these are historical tendencies only. During latent infection of a cell, HSVs express latency-associated transcript (LAT) RNA. LAT regulates the host cell genome and interferes with natural cell death mechanisms. By maintaining the host cells, LAT expression preserves a reservoir of the virus, which allows subsequent, usually symptomatic, periodic recurrences or "outbreaks" characteristic of nonlatency. Whether or not recurrences are symptomatic, viral shedding occurs to infect a new host.Шаблон:Citation needed

A protein found in neurons may bind to herpes virus DNA and regulate latency. Herpes virus DNA contains a gene for a protein called ICP4, which is an important transactivator of genes associated with lytic infection in HSV-1.[47] Elements surrounding the gene for ICP4 bind a protein known as the human neuronal protein neuronal restrictive silencing factor (NRSF) or human repressor element silencing transcription factor (REST). When bound to the viral DNA elements, histone deacetylation occurs atop the ICP4 gene sequence to prevent initiation of transcription from this gene, thereby preventing transcription of other viral genes involved in the lytic cycle.[47][48] Another HSV protein reverses the inhibition of ICP4 protein synthesis. ICP0 dissociates NRSF from the ICP4 gene and thus prevents silencing of the viral DNA.[49]

Genome

The HSV genome spans about 150,000 bp and consists of two unique segments, named unique long (UL) and unique short (US), as well as terminal inverted repeats found to the two ends of them named repeat long (RL) and repeat short (RS). There are also minor "terminal redundancy" (α) elements found on the further ends of RS. The overall arrangement is RL-UL-RL-α-RS-US-RS-α with each pair of repeats inverting each other. The whole sequence is then encapsuled in a terminal direct repeat. The long and short parts each have their own origins of replication, with OriL located between UL28 and UL30 and OriS located in a pair near the RS.[50] As the L and S segments can be assembled in any direction, they can be inverted relative to each other freely, forming various linear isomers.[51]

The open reading frames (ORFs) of HSV[28][52]
ORF Protein alias HSV-1 HSV-2 Function/description
Repeat long (RL)
ICP0/RL2 ICP0; IE110; α0 Шаблон:UniProt Шаблон:UniProt E3 ubiquitin ligase that activates viral gene transcription by opposing chromatinization of the viral genome and counteracts intrinsic- and interferon-based antiviral responses.[53]
RL1 RL1; ICP34.5 Шаблон:UniProt Neurovirulence factor. Antagonizes PKR by de-phosphorylating eIF4a. Binds to BECN1 and inactivates autophagy.
LAT LRP1, LRP2 Шаблон:UniProt
Шаблон:UniProt		 Latency-associated transcript abd protein products (latency-related protein)
Unique long (UL)
UL1 Glycoprotein L Шаблон:UniProt P28278 Surface and membrane
UL2 UL2 Шаблон:UniProt Uracil-DNA glycosylase
UL3 UL3 Шаблон:UniProt unknown
UL4 UL4 Шаблон:UniProt unknown
UL5 UL5 Шаблон:UniProt DNA replication
UL6 Portal protein UL-6 Шаблон:UniProt Twelve of these proteins constitute the capsid portal ring through which DNA enters and exits the capsid.[35][36][37]
UL7 UL7 Шаблон:UniProt Virion maturation
UL8 UL8 Шаблон:UniProt DNA virus helicase-primase complex-associated protein
UL9 UL9 Шаблон:UniProt Replication origin-binding protein
UL10 Glycoprotein M Шаблон:UniProt Surface and membrane
UL11 UL11 Шаблон:UniProt virion exit and secondary envelopment
UL12 UL12 Шаблон:UniProt Alkaline exonuclease
UL13 UL13 Шаблон:UniProt Serine-threonine protein kinase
UL14 UL14 Шаблон:UniProt Tegument protein
UL15 Terminase Шаблон:UniProt Processing and packaging of DNA
UL16 UL16 Шаблон:UniProt Tegument protein
UL17 UL17 Шаблон:UniProt Processing and packaging DNA
UL18 VP23 Шаблон:UniProt Capsid protein
UL19 VP5; ICP5 Шаблон:UniProt P89442 Major capsid protein
UL20 UL20 Шаблон:UniProt Membrane protein
UL21 UL21 Шаблон:UniProt Tegument protein[54]
UL22 Glycoprotein H Шаблон:UniProt P89445 Surface and membrane
UL23 Thymidine kinase Шаблон:UniProt Peripheral to DNA replication
UL24 UL24 Шаблон:UniProt unknown
UL25 UL25 Шаблон:UniProt Processing and packaging DNA
UL26 P40; VP24; VP22A; UL26.5 (HHV2 short isoform) Шаблон:UniProt Шаблон:UniProt Capsid protein
UL27 Glycoprotein B Шаблон:UniProt P08666 Surface and membrane
UL28 ICP18.5 Шаблон:UniProt Processing and packaging DNA
UL29 UL29; ICP8 Шаблон:UniProt Major DNA-binding protein
UL30 DNA polymerase Шаблон:UniProt DNA replication
UL31 UL31 Шаблон:UniProt Nuclear matrix protein
UL32 UL32 Шаблон:UniProt Envelope glycoprotein
UL33 UL33 Шаблон:UniProt Processing and packaging DNA
UL34 UL34 Шаблон:UniProt Inner nuclear membrane protein
UL35 VP26 Шаблон:UniProt Capsid protein
UL36 UL36 Шаблон:UniProt Large tegument protein
UL37 UL37 Шаблон:UniProt Capsid assembly
UL38 UL38; VP19C Шаблон:UniProt Capsid assembly and DNA maturation
UL39 UL39; RR-1; ICP6 Шаблон:UniProt Ribonucleotide reductase (large subunit)
UL40 UL40; RR-2 Шаблон:UniProt Ribonucleotide reductase (small subunit)
UL41 UL41; VHS Шаблон:UniProt Tegument protein; virion host shutoff[42]
UL42 UL42 Шаблон:UniProt DNA polymerase processivity factor
UL43 UL43 Шаблон:UniProt Membrane protein
UL44 Glycoprotein C Шаблон:UniProt Q89730 Surface and membrane
UL45 UL45 Шаблон:UniProt Membrane protein; C-type lectin[55]
UL46 VP11/12 Шаблон:UniProt Tegument proteins
UL47 UL47; VP13/14 Шаблон:UniProt Tegument protein
UL48 VP16 (Alpha-TIF) Шаблон:UniProt P68336 Virion maturation; activate IE genes by interacting with the cellular transcription factors Oct-1 and HCF. Binds to the sequence 5'TAATGARAT3'.
UL49 UL49A Шаблон:UniProt Envelope protein
UL50 UL50 Шаблон:UniProt dUTP diphosphatase
UL51 UL51 Шаблон:UniProt Tegument protein
UL52 UL52 Шаблон:UniProt DNA helicase/primase complex protein
UL53 Glycoprotein K Шаблон:UniProt Surface and membrane
UL54 IE63; ICP27 Шаблон:UniProt Transcriptional regulation and inhibition of the STING signalsome[56]
UL55 UL55 Шаблон:UniProt Unknown
UL56 UL56 Шаблон:UniProt Unknown
Inverted repeat long (IRL)
Inverted repeat short (IRS)
Unique short (US)
US1 ICP22; IE68 Шаблон:UniProt Viral replication
US2 US2 Шаблон:UniProt Unknown
US3 US3 Шаблон:UniProt Serine/threonine-protein kinase
US4 Glycoprotein G Шаблон:UniProt P13290 Surface and membrane
US5 Glycoprotein J Шаблон:UniProt Surface and membrane
US6 Glycoprotein D Шаблон:UniProt Q69467 Surface and membrane
US7 Glycoprotein I Шаблон:UniProt Surface and membrane
US8 Glycoprotein E Шаблон:UniProt P89475 Surface and membrane
US9 US9 Шаблон:UniProt Tegument protein
US10 US10 Шаблон:UniProt Capsid/Tegument protein
US11 US11; Vmw21 Шаблон:UniProt Binds DNA and RNA
US12 ICP47; IE12 Шаблон:UniProt Inhibits MHC class I pathway by preventing binding of antigen to TAP
Terminal repeat short (TRS)
RS1 ICP4; IE175 Шаблон:UniProt Major transcriptional activator. Essential for progression beyond the immediate-early phase of infection. IEG transcription repressor.

Gene expression

HSV genes are expressed in 3 temporal classes: immediate early (IE or α), early (E or ß) and late (γ) genes. However, the progression of viral gene expression is rather gradual than in clearly distinct stages. Immediate early genes are transcribed right after infection and their gene products activate transcription of the early genes. Early gene products help to replicate the viral DNA. Viral DNA replication, in turn, stimulates the expression of the late genes, encoding the structural proteins.[26]

Transcription of the immediate early (IE) genes begins right after virus DNA enters the nucleus. All virus genes are transcribed by host RNA polymerase II. Although host proteins are sufficient for virus transcription, viral proteins are necessary for the transcription of certain genes.[26] For instance, VP16 plays an important role in IE transcription and the virus particle apparently brings it into the host cell, so that it does not need to be produced first. Similarly, the IE proteins RS1 (ICP4), UL54 (ICP27), and ICP0 promote the transcription of the early (E) genes. Like IE genes, early gene promoters contain binding sites for cellular transcription factors. One early protein, ICP8, is necessary for both transcription of late genes and DNA replication.[26]

Later in the life cycle of HSV, expression of immediate early and early genes is shut down. This is mediated by specific virus proteins, e.g. ICP4, which represses itself by binding to elements in its own promoter. As a consequence, the down-regulation of ICP4 levels leads to a reduction of early and late gene expression, as ICP4 is important for both.[26]

Importantly, HSV shuts down host cell RNA, DNA and protein synthesis to direct cellular resources to virus production. First, the virus protein vhs induces the degradation of existing mRNAs early in infection. Other viral genes impede cellular transcription and translation. For instance, ICP27 inhibits RNA splicing, so that virus mRNAs (which are usually not spliced) gain an advantage over host mRNAs. Finally, virus proteins destabilize certain cellular proteins involved in the host cell cycle, so that both cell division and host cell DNA replication disturbed in favor of virus replication.[26]

Evolution

The herpes simplex 1 genomes can be classified into six clades.[57] Four of these occur in East Africa, one in East Asia and one in Europe and North America. This suggests that the virus may have originated in East Africa. The most recent common ancestor of the Eurasian strains appears to have evolved ~60,000 years ago.[58] The East Asian HSV-1 isolates have an unusual pattern that is currently best explained by the two waves of migration responsible for the peopling of Japan.[58]

Herpes simplex 2 genomes can be divided into two groups: one is globally distributed and the other is mostly limited to sub Saharan Africa.[59] The globally distributed genotype has undergone four ancient recombinations with herpes simplex 1. It has also been reported that HSV-1 and HSV-2 can have contemporary and stable recombination events in hosts simultaneously infected with both pathogens. All of the cases are HSV-2 acquiring parts of the HSV-1 genome, sometimes changing parts of its antigen epitope in the process.[60]

The mutation rate has been estimated to be ~1.38×10−7 substitutions/site/year.[57] In clinical setting, mutations in either the thymidine kinase gene or DNA polymerase gene have caused resistance to aciclovir. However, most of the mutations occur in the thymidine kinase gene rather than the DNA polymerase gene.[61]

Another analysis has estimated the mutation rate in the herpes simplex 1 genome to be 1.82×10−8 nucleotide substitution per site per year. This analysis placed the most recent common ancestor of this virus ~710,000 years ago.[62]

Herpes simplex 1 and 2 diverged about Шаблон:Ma.[60]

Treatment

Шаблон:Further

Similar to other herpesviridae, the herpes simplex viruses establish latent lifelong infection, and thus cannot be eradicated from the body with current treatments.[63]

Treatment usually involves general-purpose antiviral drugs that interfere with viral replication, reduce the physical severity of outbreak-associated lesions, and lower the chance of transmission to others. Studies of vulnerable patient populations have indicated that daily use of antivirals such as aciclovir[64] and valaciclovir can reduce reactivation rates.[15] The extensive use of antiherpetic drugs has led to the development of some drug resistance,Шаблон:Citation needed which in turn may lead to treatment failure. Therefore, new sources of drugs are broadly investigated to address the problem. In January 2020, a comprehensive review article was published that demonstrated the effectiveness of natural products as promising anti-HSV drugs.[65] Pyrithione, a zinc ionophore, has shown antiviral activity against herpes simplex.[66]

Alzheimer's disease

In 1979, it was reported that there is a possible link between HSV-1 and Alzheimer's disease, in people with the epsilon4 allele of the gene APOE.[67] HSV-1 appears to be particularly damaging to the nervous system and increases one's risk of developing Alzheimer's disease. The virus interacts with the components and receptors of lipoproteins, which may lead to the development of Alzheimer's disease.[68] This research identifies HSVs as the pathogen most clearly linked to the establishment of Alzheimer's.[69] According to a study done in 1997, without the presence of the gene allele, HSV-1 does not appear to cause any neurological damage or increase the risk of Alzheimer's.[70] However, a more recent prospective study published in 2008 with a cohort of 591 people showed a statistically significant difference between patients with antibodies indicating recent reactivation of HSV and those without these antibodies in the incidence of Alzheimer's disease, without direct correlation to the APOE-epsilon4 allele.[71]

The trial had a small sample of patients who did not have the antibody at baseline, so the results should be viewed as highly uncertain. In 2011, Manchester University scientists showed that treating HSV1-infected cells with antiviral agents decreased the accumulation of β-amyloid and tau protein and also decreased HSV-1 replication.[72]

A 2018 retrospective study from Taiwan on 33,000 patients found that being infected with herpes simplex virus increased the risk of dementia 2.56 times (95% CI: 2.3-2.8) in patients not receiving anti-herpetic medications (2.6 times for HSV-1 infections and 2.0 times for HSV-2 infections). However, HSV-infected patients who were receiving anti-herpetic medications (e.g., acyclovir, famciclovir, ganciclovir, idoxuridine, penciclovir, tromantadine, valaciclovir, or valganciclovir) showed no elevated risk of dementia compared to patients uninfected with HSV.[73]

Multiplicity reactivation

Multiplicity reactivation (MR) is the process by which viral genomes containing inactivating damage interact within an infected cell to form a viable viral genome. MR was originally discovered with the bacterial virus bacteriophage T4, but was subsequently also found with pathogenic viruses including influenza virus, HIV-1, adenovirus simian virus 40, vaccinia virus, reovirus, poliovirus and herpes simplex virus.[74]

When HSV particles are exposed to doses of a DNA damaging agent that would be lethal in single infections, but are then allowed to undergo multiple infection (i.e. two or more viruses per host cell), MR is observed. Enhanced survival of HSV-1 due to MR occurs upon exposure to different DNA damaging agents, including methyl methanesulfonate,[75] trimethylpsoralen (which causes inter-strand DNA cross-links),[76][77] and UV light.[78] After treatment of genetically marked HSV with trimethylpsoralen, recombination between the marked viruses increases, suggesting that trimethylpsoralen damage stimulates recombination.[76] MR of HSV appears to partially depend on the host cell recombinational repair machinery since skin fibroblast cells defective in a component of this machinery (i.e. cells from Bloom's syndrome patients) are deficient in MR.[78]

These observations suggest that MR in HSV infections involves genetic recombination between damaged viral genomes resulting in production of viable progeny viruses. HSV-1, upon infecting host cells, induces inflammation and oxidative stress.[79] Thus it appears that the HSV genome may be subjected to oxidative DNA damage during infection, and that MR may enhance viral survival and virulence under these conditions.Шаблон:Citation needed

Use as an anti-cancer agent

Шаблон:Main

Modified Herpes simplex virus is considered as a potential therapy for cancer and has been extensively clinically tested to assess its oncolytic (cancer killing) ability.[80] Interim overall survival data from Amgen's phase 3 trial of a genetically attenuated herpes virus suggests efficacy against melanoma.[81]

Use in neuronal connection tracing

Шаблон:Main

Herpes simplex virus is also used as a transneuronal tracer defining connections among neurons by virtue of traversing synapses.[82]

Other related outcomes

HSV-2 the most common cause of Mollaret's meningitis.[83] HSV-1 can lead to potentially fatal cases of herpes simplex encephalitis.[84] Herpes simplex viruses have also been studied in the central nervous system disorders such as multiple sclerosis, but research has been conflicting and inconclusive.[85]

Following a diagnosis of genital herpes simplex infection, patients may develop an episode of profound depression. In addition to offering antiviral medication to alleviate symptoms and shorten their duration, physicians must also address the mental health impact of a new diagnosis. Providing information on the very high prevalence of these infections, their effective treatments, and future therapies in development may provide hope to patients who are otherwise demoralized.Шаблон:Citation needed

Research

Шаблон:Main

There exist commonly used vaccines to some herpesviruses, such as the veterinary vaccine HVT/LT (Turkey herpesvirus vector laryngotracheitis vaccine). However, it prevents atherosclerosis (which histologically mirrors atherosclerosis in humans) in target animals vaccinated.[86][87] The only human vaccines available for herpesviruses are for Varicella zoster virus, given to children around their first birthday to prevent chickenpox (varicella), or to adults to prevent an outbreak of shingles (herpes zoster). There is, however, no human vaccine for herpes simplex viruses. As of 2022, there are active pre-clinical and clinical studies underway on herpes simplex in humans; vaccines are being developed for both treatment and prevention.Шаблон:Citation needed

References

Шаблон:Reflist

External links

Шаблон:STD/STI Шаблон:Viral cutaneous conditions Шаблон:Herpesvirales Шаблон:Baltimore classification

Партнерские ресурсы
Криптовалюты
Магазины
Хостинг
Разное

  1. ↑ 1,0 1,1 1,2 Шаблон:Cite book
  2. ↑ Шаблон:Cite journal
  3. ↑ Шаблон:Cite web
  4. ↑ Шаблон:Cite web
  5. ↑ Шаблон:Cite journal
  6. ↑ Шаблон:Cite web
  7. ↑ Шаблон:Cite web
  8. ↑ Шаблон:Cite web
  9. ↑ Шаблон:Cite journal
  10. ↑ Шаблон:Cite journal
  11. ↑ 11,0 11,1 Шаблон:Cite journal
  12. ↑ Шаблон:Cite journal
  13. ↑ Шаблон:Cite journal
  14. ↑ 14,0 14,1 Шаблон:Cite journal
  15. ↑ 15,0 15,1 Шаблон:Cite journal
  16. ↑ Шаблон:Cite web
  17. ↑ Шаблон:Cite journal
  18. ↑ Шаблон:Cite journal
  19. ↑ Шаблон:Cite journal
  20. ↑ Шаблон:Cite web
  21. ↑ Шаблон:Cite web
  22. ↑ Шаблон:Cite journal
  23. ↑ Шаблон:Cite journal
  24. ↑ Шаблон:Cite book
  25. ↑ Шаблон:Cite journal
  26. ↑ 26,0 26,1 26,2 26,3 26,4 26,5 Шаблон:Cite journal
  27. ↑ 27,0 27,1 Шаблон:Cite journal
  28. ↑ 28,0 28,1 28,2 28,3 28,4 Шаблон:Cite journal
  29. ↑ Шаблон:Cite journal
  30. ↑ Шаблон:Cite journal
  31. ↑ 31,0 31,1 Шаблон:Cite journal
  32. ↑ 32,0 32,1 Шаблон:Cite journal
  33. ↑ Шаблон:Cite journal
  34. ↑ Шаблон:Cite journal
  35. ↑ 35,0 35,1 Шаблон:Cite journal
  36. ↑ 36,0 36,1 Шаблон:Cite journal
  37. ↑ 37,0 37,1 Шаблон:Cite journal
  38. ↑ Шаблон:Cite journal
  39. ↑ Шаблон:Cite journal
  40. ↑ Шаблон:Cite journal
  41. ↑ Шаблон:Cite journal
  42. ↑ 42,0 42,1 Шаблон:Cite journal
  43. ↑ Шаблон:Cite journal
  44. ↑ Шаблон:Cite journal
  45. ↑ Шаблон:Cite journal
  46. ↑ Шаблон:Cite Q
  47. ↑ 47,0 47,1 Шаблон:Cite journal
  48. ↑ Шаблон:Cite journal
  49. ↑ Шаблон:Cite journal
  50. ↑ Шаблон:Cite book
  51. ↑ Шаблон:Cite journal
  52. ↑ Шаблон:Cite webШаблон:Dead link
  53. ↑ Шаблон:Cite journal
  54. ↑ Шаблон:Cite journal
  55. ↑ Шаблон:Cite journal
  56. ↑ Шаблон:Cite journal
  57. ↑ 57,0 57,1 Шаблон:Cite journal
  58. ↑ 58,0 58,1 Шаблон:Cite journal
  59. ↑ Шаблон:Cite journal
  60. ↑ 60,0 60,1 Шаблон:Cite journal
  61. ↑ Шаблон:Cite journal
  62. ↑ Шаблон:Cite journal
  63. ↑ Шаблон:Cite web
  64. ↑ Шаблон:Cite journal
  65. ↑ Шаблон:Cite journal
  66. ↑ Шаблон:Cite journal
  67. ↑ Шаблон:Cite journal
  68. ↑ Шаблон:Cite journal
  69. ↑ Шаблон:Cite journal
  70. ↑ Шаблон:Cite journal
  71. ↑ Шаблон:Cite journal
  72. ↑ Шаблон:Cite journal
  73. ↑ Шаблон:Cite journal
  74. ↑ Шаблон:Cite journal
  75. ↑ Шаблон:Cite journal
  76. ↑ 76,0 76,1 Шаблон:Cite journal
  77. ↑ Шаблон:Cite journal
  78. ↑ 78,0 78,1 Шаблон:Cite journal
  79. ↑ Шаблон:Cite journal
  80. ↑ Шаблон:Cite journal
  81. ↑ Шаблон:Cite press release
  82. ↑ Шаблон:Cite journal
  83. ↑ Harrisons Principles of Internal Medicine, 19th edition. p. 1179. Шаблон:ISBN.
  84. ↑ Шаблон:Cite web
  85. ↑ Шаблон:Cite journal
  86. ↑ Шаблон:Cite journal
  87. ↑ Шаблон:Cite book
Источник — http://wikihandbk.com/ruwiki/index.php?title=Английская_Википедия:Herpes_simplex_virus&oldid=15226703